Valuation: CSPC Pharmaceutical Group Limited

Market Cap 9.78TCr 1.25TCr 1.09TCr 1.02TCr 934.27Cr 1.76TCr 1,20000Cr 1.78TCr 12TCr 4.72TCr 59TCr 4.68TCr 4.58TCr 2,04000Cr P/E 2026 *
12x
P/E 2027 * 13.9x
Enterprise Value 8.71TCr 1.11TCr 975.61Cr 907.3Cr 832.56Cr 1.56TCr 1,07000Cr 1.59TCr 11TCr 4.21TCr 53TCr 4.17TCr 4.08TCr 1,81800Cr EV / Sales 2026 *
2.45x
EV / Sales 2027 * 2.39x
Free-Float
67.42%
Yield 2026 *
4.25%
Yield 2027 * 4.31%
24/07 CSPC Pharmaceutical Group Limited Announces Marketing Approval For Paliperidone Palmitate Injection CI
22/07 CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial of Sys6026 Injection for HPV Type 16 or 18 Related Cervical High Grade Squamous Intraepithelial Lesion in China CI
17/07 CSPC Pharmaceutical Group Limited Announces New Drug Application for Trastuzumab Envedotin Injection Accepted by Nmpa CI
17/07 CSPC Pharma's Application for Breast Cancer Drug Candidate Accepted in China MT
16/07 CSPC Pharma Begins Two Drug Trials in China MT
15/07 CSPC Pharma's Breast Cancer Drug Combination Granted China Breakthrough Designation MT
14/07 CSPC Pharmaceutical Group Limited Announces Docetaxel for Injection (Albumin-Bound) and Anbenitamab Receives Breakthrough Therapy Designation in China for First-Line Treatment of Advanced HER2-Positive Breast Cancer Co-Developed by Shanghai JMT-BIO Technology Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd CI
07/07 Weight-loss drug developers line up to tap lucrative market as competition heats up RE
07/07 CSPC Pharma Begins Phase II Trial of Mixed Hyperlipidaemia Drug MT
07/07 CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial Of SYH2070 Injection For Treatment Of Mixed Hyperlipidaemia At First Centre In China CI
02/07 European Stocks Surge, Oil Prices Drop; Defense, Luxury Shares Rally MT
02/07 CSPC Pharma Begins Tumor Drug Trial in China MT
02/07 AstraZeneca Collaborating With CSPC Pharma in siRNA Drug Deal Worth Up to $1.77 Billion MT
1 day+2.15%
1 week+5.56%
Current month+22.67%
1 month+28.57%
3 months-4.79%
6 months-12.84%
Current year+1.42%
1 week 8.12
Extreme 8.12
8.86
1 month 6.65
Extreme 6.65
8.86
Current year 6.53
Extreme 6.53
10.96
1 year 6.53
Extreme 6.53
11.63
3 years 4.27
Extreme 4.27
11.63
5 years 4.27
Extreme 4.27
11.9
10 years 3.47
Extreme 3.4687
13.93
Manager TitleAgeSince
Chief Executive Officer 46 19/12/2025
Chief Operating Officer 56 19/12/2025
Corporate Officer/Principal 44 01/07/2024
Director TitleAgeSince
Chairman 72 26/08/2011
Director/Board Member 56 20/01/2012
Director/Board Member 66 21/12/2012
Date Insider Type Main position Quantity % Market Cap.
23/06/26 Other

Chief Operating Officer

-14,00,000 0.0122%
23/06/26 Other

Director

-7,00,000 0.0061%
22/06/26 Other

Chairman

1,46,50,000 0.1271%
Change 5-day change 1-year change 3-year change Capi.($)
+2.15%+5.56%-0.93%+33.80% 1.25TCr
+0.86%+1.43%+47.17%+161.40% 1,06700Cr
+1.59%+4.09%+56.51%+52.79% 63TCr
+0.95%+1.91%+36.30%+83.13% 46TCr
+1.60%+6.25%+37.00%+30.00% 35TCr
-0.60%+1.52%+36.67%+39.80% 30TCr
-0.14%+0.60%+17.29%+18.19% 26TCr
+0.09%-2.82%-29.09%-41.29% 22TCr
+1.22%+2.66%+22.66%+59.81% 20TCr
-1.18%-3.70%+11.28%+67.43% 16TCr
Average +0.65%+1.92%+23.49%+50.51% 36.56TCr
Weighted average by Cap. +0.77%+2.09%+35.87%+78.00%

Financials

2026 *2027 *
Net sales 3.56TCr 453.62Cr 398.41Cr 370.52Cr 340Cr 638.83Cr 44TCr 648.68Cr 4.4TCr 1.72TCr 21TCr 1.7TCr 1.67TCr 74TCr 3.51TCr 447.99Cr 393.47Cr 365.92Cr 335.78Cr 630.9Cr 43TCr 640.62Cr 4.35TCr 1.7TCr 21TCr 1.68TCr 1.65TCr 73TCr
Net income 786.41Cr 100.28Cr 88Cr 82Cr 75Cr 141.22Cr 9.66TCr 143.4Cr 972.63Cr 380Cr 4.75TCr 376.45Cr 368.34Cr 16TCr 692.01Cr 88Cr 78Cr 72Cr 66Cr 124.27Cr 8.5TCr 126.19Cr 855.88Cr 334.38Cr 4.18TCr 331.26Cr 324.12Cr 14TCr
Net Debt -1.06TCr -135.69Cr -119.18Cr -110.83Cr -101.71Cr -191.1Cr -13TCr -194.04Cr -1.32TCr -514.2Cr -6.42TCr -509.4Cr -498.42Cr -22TCr -1.38TCr -175.33Cr -154Cr -143.21Cr -131.42Cr -246.92Cr -17TCr -250.73Cr -1.7TCr -664.41Cr -8.3TCr -658.21Cr -644.02Cr -29TCr
Logo CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.
Employees
19,700
Date Price Change Volume
24/26/24 HK$8.550 +2.15% 13,62,79,490
23/26/23 HK$8.370 -0.36% 2,95,76,730
22/26/22 HK$8.400 -0.12% 6,52,82,728
21/26/21 HK$8.410 -1.06% 5,68,58,983
20/26/20 HK$8.500 +4.94% 8,59,44,318
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
8.550HKD
Average target price
11.47HKD
Spread / Average Target
+34.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 1093 Stock